Could Hyaluronic acid (HA) reduce Bacillus Calmette-Guérin (BCG) local side effects? Results of a pilot study

BMC Urology

Volumn 14, Issue 1, 2014, Pages

  Topazio, Luca ^a   Miano, Roberto ^a   Maurelli, Valentina ^a   Gaziev, Gabriele ^a   Gacci, Mauro ^b   Iacovelli, Valerio ^a   Finazzi Agrò, Enrico ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

BCG; Hyaluronic acid; Non bacterial cystitis; Non muscle invasive bladder cancer

Indexed keywords

BCG VACCINE; HYALURONIC ACID; IMMUNOLOGICAL ADJUVANT;

ADULT; ARTICLE; BURNING SENSATION; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CYSTALGIA; CYSTOSCOPY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSURIA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MALE; MICTURITION; NON MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; URINARY FREQUENCY; URINARY URGENCY; URINE CYTOLOGY; VISUAL ANALOG SCALE; AGED; CHEMICALLY INDUCED; MIDDLE AGED; PAIN; PROSPECTIVE STUDY; URINARY BLADDER NEOPLASMS; URINATION DISORDERS; VERY ELDERLY;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; BCG VACCINE; FEMALE; HUMANS; HYALURONIC ACID; MALE; MIDDLE AGED; PAIN; PILOT PROJECTS; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; URINATION DISORDERS;

EID: 84908019144     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-14-64     Document Type: Article

References (29)

1. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. Gontero P, Bohle A, Malmstrom PU, O'Donnell MA, Oderda M, Sylvester R, Witjes F, Eur Urol 2010 57 3 410 429 doi:10.1016/j.eururo.2009.11.023. Epub 2009 Nov 13
2. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A, Debruyne FM, J Urol 1992 147 3 596 600
3. Drug-induced bladder and urinary disorders. Incidence, prevention and management. Drake MJ, Nixon PM, Crew JP, Drug Saf 1998 19 1 45 55
4. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Witjes JA, Palou J, Soloway M, Lamm D, Brausi M, Spermon JR, Persad R, Buckley R, Akaza H, Colombel M, Böhle A, Eur Urol Suppl 2008 7 10 667 674
5. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. Vegt PD, van der Meijden AP, Sylvester R, Brausi M, Höltl W, de Balincourt C, J Urol 1997 157 4 1246 1249
6. The effect of ofloxacin on bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double blind, placebo controlled, multicenter study. Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P, J Urol 2006 176 935
7. Does ofloxacin protect against BCG related toxic effects in patients with bladder cancer? O'Donnell M, Nat Clin Pract Urol 2007 4 304
8. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. Martínez-Piñeiro JA, Flores N, Isorna S, Solsona E, Sebastián JL, Pertusa C, Rioja LA, Martínez-Piñeiro L, Vela R, Camacho JE, Nogueira JL, Pereira I, Resel L, Muntañola P, Galvis F, Chesa N, De Torres JA, Carballido J, Bernuy C, Arribas S, Madero R, for CUETO (Club Urológico Español de Tratamiento Oncológico), BJU Int 2002 89 7 671 680
9. Intravesical glycosaminoglycans in the management of chronic cystitis. Iacovelli V, Topazio L, Gaziev G, Bove P, Vespasiani G, Finazzi Agrò E, Minerva Urol Nefrol 2013 65 4 249 262
10. GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans-a review. Madersbacher H, van Ophoven A, van Kerrebroeck PE, Neurourol Urodyn 2013 32 1 9 18 doi:10.1002/nau.22256. Epub 2012 Jul 10
11. Treatment of acute iatrogenic cystitis secondary to bladder chemo-immuno-instillation or pelvic radiotherapy. Sommariva ML, Sandri SD, Guerrer CS, Urologia 2010 77 187
12. Intravesical sodium hyaluronate (Cystistat®) as a treatment for chronic BCG Cystitis: a discussion of two successful cases. Fowler S, Daukeh M, Thompson A, [ http://www.bjui.org/ContentFullItem.aspx?id=638 ]
13. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K, Eur Urol 2006 49 3 466 4755 discussion 475-7. Epub 2006 Jan 17
14. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, Mason MD, BJU Int 2001 88 3 209 216
15. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Han RF, Pan JG, Urology 2006 67 6 1216
16. Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. Böhle A, Bock PR, Urology 2004 63 4 682
17. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. Sylvester RJ, van der Meijden AP, Lamm DL, J Urol 2002 168 5 1964
18. Maintenance bacillus Calmette-Guerin for TaT1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Van der Meijden APM, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV, EORTC Genito-Urinary Tract Cancer Group, Eur Urol 2003 44 429
19. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED, J Urol 2000 163 4 1124 1129
20. Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer. Saint F, Irani J, Patard JJ, Salomon L, Hoznek A, Zammattio S, Debois H, Abbou CC, Chopin DK, Urology 2001 57 5 883 888
21. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E, Rodríguez RH, Gómez JM, Martín MG, Molina JR, Collado AG, Flores N, Isorna S, Pertusa C, Rabadán M, Astobieta A, Camacho JE, Arribas S, Madero R, Club Urológico Español de Tratamiento Oncológico (CUETO), J Urol 2005 174 4 Pt 1 1242 1247
22. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, Hoeltl W, Turkeri L, Marreaud S, Collette S, Oosterlinck W, Eur Urol 2013 63 3 462 472 doi: 10.1016/j.eururo.2012.10.039. Epub 2012 Nov 2
23. Recent developments of intravesical therapy of painful bladder syndrome/interstitial cystitis: a review. Toft BR, Nordling J, Curr Opin Urol 2006 16 268
24. A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. Nickel JC, Egerdie B, Downey J, Singh R, Skehan A, Carr L, Irvine-Bird K, BJU Int 2009 103 1 56 60 doi:10.1111/j.1464-410X.2008.08028.x. Epub 2008 Sep 3
25. Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. Hurst RE, World J Urol 1994 12 3
26. Effect of diagnostic hydrodistension and four intravesical Hyaluronan Instillations on bladder ICAM-1 intensity and association of ICAM-1 intensity with clinical response in patients with interstitial cystitis. Leppilahti M, Hellström P, Tammela TLJ, Urology 2002 60 46
27. Anti-inflammatory action of a hyaluronic acid-chondroitin sulphate preparation in an in vitro bladder model. Schulz A, Vestweber AM, Dressler D, Akt Urol 2009 40 2 109
28. Intravesical sodium hyaluronate inhibits the rat urinary mast cell mediator increase triggered by acute immobilization stress. Boucher WS, Letourneau R, Huang M, Kempuraj D, Green M, Sant GR, Theoharides TC, J Urol 2002 167 1 380 384
29. The side effects of bacillus Calmette-Guérin in the treatment of TaT1 bladder cancer do not predict its efficacy: results from a European Organization for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Sylvester RJ, van der Meijden APM, Oosterlinck W, Hoeltl W, Bono AV, EORTC Genito-Urinary Tract Cancer Group, Eur Urol 2003 44 423